Literature DB >> 33515317

Management of perianal fistula in inflammatory bowel disease: identification of prognostic factors associated with surgery.

Sara Gortázar de Las Casas1, Mario Alvarez-Gallego2, Jose Antonio Gazo Martínez2, Natalia González Alcolea2, Cristina Barragán Serrano2, Aitor Urbieta Jiménez2, María Dolores Martín Arranz3, Jose Luis Marijuan Martín2, Isabel Pascual Migueláñez2.   

Abstract

PURPOSE: As one of the clinical manifestations of inflammatory bowel disease (IBD), perianal fistula disease (PFD) can potentially impact the patient quality of life. The management of PFD employs a multidisciplinary approach which includes antibiotics, biological therapies, immunomodulators, and surgery. We analyzed the outcome and prognostic factors of anal fistula surgery in IBD patients.
METHODS: We conducted a retrospective study of IBD patients undergoing elective surgery for anal fistula between January 2015 and December 2018 at our University Department of Surgery. We collated demographic factors, disease activity, imaging (MRI and endoanal ultrasound), surgical interventions, and medical treatment assessing the rate of fistula closure and fecal incontinence, 2 months and 1 year after surgery.
RESULTS: Thirty-five IBD patients with anal fistula underwent surgery (28 Crohn's disease, four ulcerative colitis, and three indeterminate colitis). Twenty-seven patients presented with complex fistulas and eight with simple fistulas with 10 patients undergoing single-stage surgery. In 25 patients, a two-stage surgical approach was planned and performed (draining seton plus medical treatment and then second-stage surgery with curative intent). At 1 year of follow-up, the fistula healing rate was 50% for single-stage surgery and 60% for two-stage surgery (P = 0.09). Overall, 19.2% of patients developed postoperative fecal incontinence. A time interval greater than 12 months between surgeries is a favorable prognostic factor for fistula healing with the two-stage approach (P = 0.002).
CONCLUSIONS: In our retrospective study, two-stage surgery in IBD patients presenting with complex perianal fistulous disease results in a better medium-term outcome with a longer time interval between surgeries.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Perianal fistula; Surgical treatment

Year:  2021        PMID: 33515317     DOI: 10.1007/s00423-021-02100-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  8 in total

1.  MR imaging classification of perianal fistulas and its implications for patient management.

Authors:  J Morris; J A Spencer; N S Ambrose
Journal:  Radiographics       Date:  2000 May-Jun       Impact factor: 5.333

Review 2.  Management of anoperineal lesions in Crohn's disease: a French National Society of Coloproctology national consensus.

Authors:  D Bouchard; F Pigot; G Staumont; L Siproudhis; L Abramowitz; P Benfredj; C Brochard; N Fathallah; J-L Faucheron; T Higuero; Y Panis; V de Parades; B Vinson-Bonnet; D Laharie
Journal:  Tech Coloproctol       Date:  2019-01-02       Impact factor: 3.781

3.  Prevalence and correlates of major depression in Granada, Spain: Results from the GranadΣp study.

Authors:  Alejandro Porras-Segovia; Eulalio Valmisa; Blanca Gutiérrez; Isabel Ruiz; Miguel Rodríguez-Barranco; Jorge Cervilla
Journal:  Int J Soc Psychiatry       Date:  2018-05-29

4.  Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

Authors:  Julián Panés; Damián García-Olmo; Gert Van Assche; Jean Frederic Colombel; Walter Reinisch; Daniel C Baumgart; Axel Dignass; Maria Nachury; Marc Ferrante; Lili Kazemi-Shirazi; Jean C Grimaud; Fernando de la Portilla; Eran Goldin; Marie Paule Richard; Mary Carmen Diez; Ignacio Tagarro; Anne Leselbaum; Silvio Danese
Journal:  Gastroenterology       Date:  2017-12-24       Impact factor: 22.682

5.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Authors:  Julián Panés; Damián García-Olmo; Gert Van Assche; Jean Frederic Colombel; Walter Reinisch; Daniel C Baumgart; Axel Dignass; Maria Nachury; Marc Ferrante; Lili Kazemi-Shirazi; Jean C Grimaud; Fernando de la Portilla; Eran Goldin; Marie Paule Richard; Anne Leselbaum; Silvio Danese
Journal:  Lancet       Date:  2016-07-29       Impact factor: 79.321

6.  Is MRI healing the target in treating perianal fistulizing Crohn's disease?

Authors:  Al Sulais Eman; Sebastian Shaji
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-02       Impact factor: 2.566

Review 7.  Diagnosis and management of fistulizing Crohn's disease.

Authors:  Ole Haagen Nielsen; Gerhard Rogler; Dieter Hahnloser; Ole Østergaard Thomsen
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-01-20

8.  Assessing the activity of perianal Crohn's disease: comparison of clinical indices and computer-assisted anal ultrasound.

Authors:  Alessandra Losco; Chiara Viganò; Dario Conte; Bruno Mario Cesana; Guido Basilisco
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.